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Abstract 
Introduction 
Natalizumab is a humanized monoclonal antibody highly effective in relapsing-remitting multiple 
sclerosis (MS). Important concerns about its safety have been pointed out because of the risk of 
progressive multifocal leukoencephalopathy (PML), caused by the opportunistic John-Cunningham 
virus (JCV).  
Areas covered 
This review analyzes all the safety aspects related to the use of natalizumab in MS patients. Fatigue 
and allergic reactions are not-severe adverse events (AEs) occurring more frequently than placebo 
and no differences in serious AEs (SAE) have been observed comparing to interferon-β1a during 
clinical trials. No clear teratogenic effects have been observed, but natalizumab is still considered a 
pregnancy category "C" drug.  
The risk of PML depends on 3 factors: concomitant or previous immunosuppression, exposure 
duration, and anti–JCV antibody level. In natalizumab-related PML the average survival is 77%; 
prognostic features and information for the earliest identification of PML have been identified to 
maximally reduce its incidence, mortality and morbidity. In addition, a few other safety issues need 
to be taken into account. 
Expert opinion 
Natalizumab is a highly effective drug for MS patients but its safety issues represent a relevant 
limitation and impose strict clinical surveillance of treated patients. No significantly higher 
difference in SAEs occurrence was observed during the clinical trials, in spite of PML. Other post-
marketing safety red-flags have been pointed out, and if PML and its consequences are considered 
the most relevant issues for natalizumab patients, a continuous surveillance must be maintained in 
all patients also regarding other possible SAEs like liver diseases and malignancies. 
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1) Introduction 
Multiple sclerosis (MS) is a frequent chronic inflammatory disease affecting the central nervous 
system (CNS) [1]. Recent data report that MS affects over 2.3 million people in the world and 
85%–90% of patients experience relapsing and remitting course (RR) of neurologic symptoms [2]. 
The intermittent formation of inflammatory lesions in brain and spinal cord is the hallmark of 
RRMS, with the development of demyelinating plaques and axonal loss [3]. The formation of MS 
inflammatory lesions in CNS is primarily referred to a lymphocyte migration across the blood–brain 
barrier [BBB][3]. The process of lymphocyte migration in the CNS inflammation areas is mediated 
by the interaction between the α4-β1 integrin (a lymphocyte surface protein) and the vascular-cell 
adhesion molecule 1 (VCAM-1), expressed on the surface of endothelial cells of the BBB vessels 
[4]–[8]. 
 
2) Mechanisms of action, pharmacodynamics and pharmacokinetics of natalizumab 
Natalizumab (Tysabri®, Biogen, Boston, USA) is a humanized monoclonal antibody (MAb) against 
the α4 subunit of α4-β1 and α4-β7 integrins; its main mechanism of action is the blockade of the 
binding of the α4 integrins to their endothelial receptors (VCAM-1 and mucosal addressin-cell 
adhesion molecule-1), preventing inflammatory cells from crossing the BBB and entering the CNS 
[9], [10]. Another supposed mechanism of action of natalizumab is the modulation of ongoing 
inflammatory reactions by inhibiting the binding between α4-leukocytes and both fibronectin and 
osteopontin, thus modulating the leukocyte activation and proliferation within the CNS [11], [12]. 
The pharmacokinetics of natalizumab was analyzed in a phase I, randomized, placebo-controlled,   
dose-escalating  trial in MS patients [13]; in this study the maximum serum concentrations and area 
under the curve (AUC) values for natalizumab resulted proportional to the administered dose [13]. 
Natalizumab shows a mean half-life of 16 ± 4 days with a clearance of 13.1 ± 5 ml/hour[14]. In the 
pharmacokinetics study [13] the body weight, in the range of 40-100 kg, did not significantly 
influenced the clearance of natalizumab; this justified the use of a fixed dose of 300 mg every 28 
days. In addition the Authors found a plateau effect for efficacy at doses of 300 mg or more[13].  
Natalizumab determines a mean α4-integrin saturation levels greater than 70% at 4 weeks after 
administration [15], the drug is measurable in circulation for up to 12 weeks and variations in in the 
distribution of cerebrospinal fluid (CSF) cells were detectable for about 6 months after natalizumab 
interruption[16].  
 
3) Review of clinical utility 
In 2004 natalizumab was introduced in the market after the US Food and Drug Adminsitration 
(FDA) approval for its use in RRMS, upon the interim analysis of 2 phase-III trials, the AFFIRM 
and SENTINEL studies [17], [18]. 
These trials reported the great efficacy of natalizumab in RRMS, demonstrating a relevant reduction 
of the annualized relapse rate (ARR) as compared with placebo (0.26 for the natalizumab group vs. 
0.81 for the placebo group) [17] and leading to a new goal in MS therapy: the “freedom from 
disease activity” [19]. However, natalizumab was temporarily withdrawn from the market after the 
occurrence of 3 cases of progressive multifocal leukoencephalopathy (PML) in 2 MS patients and in 
one patient treated for Crohn's disease [20]–[22]. 
Given to its efficacy, natalizumab was reintroduced into the market and released in the European 
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Union in 2006, together with a Global Risk Management Plan. In particular, the "TOUCH®" 
program (TYSABRI Outreach: Unified Commitment to Health Prescribing Program) [23] has been 
developed in conjunction with the FDA to facilitate the appropriate use of natalizumab and to assess 
the natalizumab-associated incidence and risk factors for PML and other opportunistic infections. 
As of September 2016, approximately 161.300 patients received natalizumab in post-marketing 
setting worldwide, and as of December 2016, 698 treated patients reported a confirmed PML [24]. 
Some other adverse events are associated to the every 28 day i.v. infusion of natalizumab, 
encompassing liver diseases, infections, reported to occur in 1.9–4% of patients, opportunistic 
infections other than PML, with an incidence of 0.2%-1%, hypersensitivity reactions and 
anaphylaxis, occurring in 0.2%-1.3% of patients [17], [18], [25], [26]. Overall, these adverse events 
have a marginal negative impact in the management of patients treated with natalizumab, in 
consideration of their low incidence, morbidity and mortality rate, and given the high efficacy of the 
treatment; on the contrary, the risk of PML represents a critical limiting factor in natalizumab start 
or continuation. Additionally, there are a few authors reporting the onset of lymphoproliferative 
disorders in natalizumab treated patients; these represent serious and potentially fatal AEs although 
their low incidence and the lack of biological evidences raised doubts on the cause-effect 
correlation with the use of natalizumab.  
This paper reviews all the available data on natalizumab safety, analyzing and discussing all the 
issues related to the natalizumab therapy. In the context of an increasing armamentarium of 
approved MS treatments and a more complex management of MS patients, this review aims to 
provide updated information and to discuss the potential risks correlated to the use of one of the 
most efficacious disease-modifying therapy for MS. 
For this review, a PubMed search was performed using the terms “natalizumab", "natalizumab AND 
multiple sclerosis”, “natalizumab AND PML”, “natalizumab AND safety”, "natalizumab AND side 
effects" without time restriction. 
 
4) Adverse events other than PML  
Including MS relapses, the global incidence of serious adverse events (SAE) reported in the phase-
III clinical trials AFFIRM and SENTINEL [17], [18] is 19% and 18% respectively. In the AFFIRM 
trial [13] 6% of patients had a MS relapse, 3.2% a serious infection (4 cases of pneumonia, 5 cases 
of urosepsis and various other infection encompassing pilonidal cyst infection, cellulitis, febrile 
infection, gastroenteritis, cryptosporidial diarrhea, mononucleosis, osteomyelitis, sinusitis, 
tonsillitis, viral infection, appendicitis, and an infection of unclear cause), <1% malignancies (3 
breast cancers, 1 cervical cancer and 1 malignant melanoma), 27% fatigue. Infusion reactions are 
defined as any event that occurred within two hours after the start of the one-hour infusion and 
occurred in 24% of patients; the most common infusion reaction was headache (5%), while 4% of 
patients had a hypersensitivity reaction: 12 cases of urticaria or generalized urticaria, 1 of allergic 
dermatitis, 8 of a reaction called hypersensitivity and 5 of anaphylactoid reactions (urticaria plus 
other signs) [17]. In the AFFIRM study, the only adverse events significantly more frequent in the 
natalizumab than in the placebo group were fatigue (27% versus 21%) and allergic reaction (9% 
versus 4%) [17]. 
In the SENTINEL trial [18] 5% of patients treated with natalizumab plus interferon-β1a had a MS 
relapse, 2.7% had a serious infection, encompassing viral infections and urosepsis, 1% 
malignancies, 24% infusion reactions (1.9% hypersensitivity reaction without cardiopulmonary 
compromise). No SAEs had a statistically significant higher incidence between combination therapy 
and interferon-β1a alone group; the mild adverse events associated with combination therapy were 
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anxiety, pharyngitis, sinus congestion, and peripheral edema. In the open label, prospective, multi-
national, single-arm post-marketing safety STRATA study [25] on 1094 MS patients receiving a 
median of 56 infusions, 16% reported at least one SAE (excluding MS relapse): 4% infections and 
infestations, 2% gastrointestinal disorders, 2% neoplasms (benign, malignant and unspecified). 
Infusion reactions were experienced by 5% of patients (more frequently during the second or third 
infusion). 
The TOP study [26], another large post-marketing open-label 10-year prospective study, observed 
4821 natalizumab treated subjects, reporting 2,6% of patients with a SAE related or possibly related 
to natalizumab. The most common SAE was infection (1.9%); the serious hypersensivity reaction 
incidence was 0.5%, while malignancies occurred in 0,5% of patients (12 different types of 
malignancies reported). 
Regarding the presence of natalizumab antibodies, 9% had detectable antibodies at some time 
during the AFFIRM study and 6% reported persistent antibodies with an increase in infusion-related 
adverse events and a loss of efficacy of therapy [17]. In the SENTINEL study, 12% of the 
combination-therapy group had antibodies to natalizumab, but only 6% reported persistent anti-
natalizumab antibodies, resulting in a loss of efficacy and an increase in infusion-related adverse 
events [18]. In the post-marketing STRATA and TOP studies [25], [26], about 3% of patients were 
found persistently positive for anti-natalizumab antibodies, even though in the latter study the 
antibody status data were not collected routinely. In the TOP study [26] the presence of anti-
natalizumab antibodies was listed as a reason for discontinuing the therapy. 
As a known pharmacodynamic effect, increases in the number of lymphocytes, monocytes, 
eosinophils, basophils and also nucleated red cells were seen in patients treated with natalizumab, in 
absence of elevation in the number of neutrophils. All changes reported were not correlated with 
clinical effects [17], [18]. 
While the clinical trials AFFIRM and SENTINEL [17], [18] reported a similar incidence of 
hepatobiliary disorders between the patients treated with natalizumab and the control groups, the 
Post-Marketing FDA Adverse Reaction Reporting System (FAERS) contains 628 cases of different 
degrees of liver injury associated with natalizumab from 2009 to 2014, comprising 22 cases of liver 
failure and 12 cases of autoimmune hepatitis [27]. To date, 12 case reports of significant liver injury 
associated with natalizumab are described [27], 50% of which with autoimmune hepatitis antibodies 
and compatible biopsy. Monitoring of liver function is recommended for patients treated with 
natalizumab. The adverse events other than PML are summarized in Table 1. 
  
5) Pregnancy 
Experience concerning the influence of natalizumab on fertility and pregnancy is limited. In animal 
studies, natalizumab proved alteration of fertility in females, but not in males; however, no clear 
teratogen effects have been observed nowadays, and normal outcomes of pregnancy have been 
reported in some published cases of patients treated for the whole gestational period [28], [29]. A 
study with a small case series, on the contrary, found mild hematological alterations in 10 of 13 
children of mothers receiving natalizumab during the 3rd pregnancy trimester [30]. 
Nowadays there are no controlled data in human pregnancy and the effects of natalizumab on 
fertility, pregnancy and breastfeeding still need to be ascertained [31], [32]. Thus, at the time of 
prescription, patients must be correctly informed of the possible consequences of the drug on 
fertility and of the need for contraception. At the same time, pregnancy should be planned in 
advance and the treatment suspension evaluated in a pre-conception time period adapted to the half-
life of the drug [33]. To date, natalizumab is a pregnancy category "C" drug [34]. 
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Breastfeeding is contraindicated in natalizumab treated patients since it is excreted into human milk. 
Although the drug is not orally bioavailable, the effects of exposure on infants are unknown and a 
decision to discontinue breastfeeding or discontinue the drug should be made [35]. 
 
6) PML and immune reconstitution inflammatory syndrome" (IRIS) 
The most important concern regarding the use of natalizumab is related to the possible occurrence 
of PML, an infective CNS disease caused by the John Cunningham virus (JCV) reactivation [36], 
[37]. JCV infection often occurs in early life and it is typically asymptomatic or mildly 
symptomatic, in absence of CNS involvement; then, JCV, a member of the polyoma family, 
presumably has a whole-life persistence in human body, remaining latent in various tissues, 
encompassing the kidneys, the bone marrow and the lymphoid tissues [38], [39]. In the general 
population a 60-70% prevalence of detectable anti-JCV antibodies has been estimated, with the 
prevalence of seropositive subjects increasing with the age [38]. PML may result from the 
reactivation of latent JCV infection in the brain [40] or spread from peripheral reservoirs in the 
kidneys [41] and bone marrow [42] to the brain. The disease affects severely immunosuppressed 
patients in terms of T-lymphocyte response [39], with a JCV infection primarily involving the 
myelin-producing oligodendrocytes and causing severe demyelination [40]–[43]. PML infection 
seems to be more widespread in the brain, since histological observations of JCV are reported also 
in cerebellum, astrocytes and neuronal cells [44]–[47]. 
PML has never been reported in MS prior to introduction of natalizumab. The diagnosis of PML in 
a clinical setting is based on the clinical presentation, imaging findings and the detection of the 
virus in the CSF using quantitative Polymerase Chain Reaction (PCR); however, the gold standard 
for the diagnosis of PML is represented by the presence of JCV in histopathology examination of 
biopsy material [48], [49]. 
PML is a well known disease in the field of human immunodeficiency virus epidemiology, where it 
represents a complication of the pathological immunosuppression in about 5% of patients [50]; 
moreover, the wide use of immunosuppressive treatments in the last decades, including alkylating 
agents and monoclonal antibodies, has given the contribute to the onset of further cases. The 
clinical presentation of PML is variable with behavioral, motor, language, and visual symptoms as 
possible first manifestation of the disease; cognitive changes in particular seem to be more frequent 
in MS natalizumab-treated patients developing PML, possibly because of the multifocal 
demyelinating lesions already present in these patients [51]. Visual symptoms are reported in one-
quarter to one-half of all PML patients, typically presenting as a field deficit [52] related to the 
involvement of the visual pathways and not as a direct damage of the optic nerve, never described 
in PML patients. Seizures can occur in up to one-third of PML cases and are more frequent in cases 
of juxta-cortical lesions [53]. 
Distinguishing PML from an acute MS attack can be difficult, as the general symptoms can be 
similar to the symptoms of an MS relapse. However, the early diagnosis of PML is pivotal since 
patients whose immune functions can be restored could have an improvement in terms of survival 
and sequelae [54], [55]. Following natalizumab approval, experience from a higher number of 
patients treated for a long time period is providing greater accuracy in PML risk estimation. The 
current known risk factors for JCV reactivation in natalizumab patients are: concomitant or 
previous immunosuppression and natalizumab exposure duration, particularly after the 24th 
administration [36]. More recently, the anti–JCV antibody level in serum or plasma has been 
identified as a further risk of natalizumab-associated PML [56]. According to these data, the 
European Medicines Agency (EMA) has recently updated the estimate risk for PML in seropositive 
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JCV antibody patients treated with natalizumab [57]; the risk is small at antibody index values of 
0.9 or less (0.1 – 0.6/1000), and increases substantially in patients with index values above 1.5 who 
have been treated for more than 24 administrations (0.9 – 10/1000) [54]. Patients with previous 
immunosuppressant therapy after 24 doses have a PML risk ranging from 0.4 – 10/1000 [55]. 
Following EMA recommendations, after the 24th natalizumab dose, patients should be informed 
again about the risk of PML with natalizumab and they are asked to provide a standardized written 
consent form to continue this therapy [58]. Indeed, after the 24th natalizumab dose, patients should 
reevaluate with the neurologist the opportunity to continue natalizumab, to switch to any other first 
or second line MS treatment or, alternatively to quit all therapies. Moreover, patients should be 
informed to be vigilant about the risk of PML for up to 6 months after discontinuation of 
natalizumab [58]. 
PML usually presents in magnetic resonance imaging (MRI) as one or more areas of 
hyperintensitity on T2/FLAIR sequences in the white matter with a peripheral, bilateral and 
asymmetric distribution. Little irregular signal intensity within the lesions can have a punctate 
microcystic appearance [59], [60]. This finding has been suggested to represent small areas of 
demyelination in the immediate vicinity of infected oligodendrocytes or early immune response 
within perivascular spaces [61]. Small punctate T2 lesions may be seen in proximity to the lesions. 
These vary in shape and size, growing and becoming confluent as the disease progresses [57], [58]. 
PML lesions have subcortical rather than periventricular location and affect U-fibers; FLAIR is the 
preferred sequence for PML diagnosis, because of its subcortical location. The border is ill-defined 
toward the white matter and sharp toward the cortical grey matter (GM).  Cortical GM involvment 
is seen in 50% of cases. On T1 weighted imaging lesions become increasingly hypointense, as 
white matter destruction occurs. No mass effect is present even in large lesions apart from when 
inflammatory response occurs [60]. Posterior fossa involvement encompasses the cerebellum and 
middle cerebellar peduncles and, rarely, the brainstem with a “crescent” shape. Optic nerves and 
spinal cord are spared [59]. 
At the early asymptomatic stage MRI shows focal hyperintense T2 signal in the juxta-cortical white 
matter, most commonly unilobar in the frontal lobe, involving U-fibers and also quite frequently the 
adiacent grey matter [59], [62]. Compared with other PML populations, contrast-enhancement can 
be observed quite frequently in natalizumab-associated PML, occurring in about 30-40% of the 
cases at the time of diagnosis [59], [62]. 
The pattern of enhancement is variable and may be patchy, linear, nodular, peripheral or 
perivascular. It suggests that an inflammatory response is involved. Enhancement at time of 
diagnosis seems to be correlated with decreased survival and greater disability [59]. 
Diffusion weighted MR imaging (DWI) varies depending on the stage of the disease and can be 
negative in asymptomatic patients, probably because the degree of oligodendrocytic and astrocytic 
damage is milder. Spectroscopy findings in PML are non specific and not useful in differentiate 
PML lesions from MS relapses [59]. 
Data are emerging about the evidence of PML six months before the onset of symptoms [63]. 
Recommendations from an expert group [60], based on the opinion of authors, in the absence of 
peer-reviewed evidence of the predictive values of MRI at different time points prior to PML 
diagnosis, indicate that all new patients should be scanned prior to initiating therapy and at least 
annually on treatment. After 18 months of therapy the frequency of MRI depends on JCV status and 
– for anti-JCV positive patients – their index. After this time brain MRI is recommended every 6 
months for index ≤ 1.5 and every 3-4 months for index > 1.5 [60]. 
One of the most concerns after the diagnosis of PML and the prompt withdrawal of natalizumab is 
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the almost inevitable occurrence of the "immune reconstitution inflammatory syndrome" (IRIS). 
IRIS typically presents as a sub-acute progression and exacerbation of earlier symptoms of PML 
within days to weeks after natalizumab withdrawal and/or plasma exchange therapy (PLEX) for the 
faster removal of the drug from the blood [51]. 
IRIS is an inflammatory response to clinically apparent or subclinical pathogens, associated with 
recovery of the immune system after a period of immunosuppression [39]. This immune 
reconstitution is inferred by an increase in T-lymphocyte counts, which usually follows the 
commencement of antiretroviral therapy in HIV (Human Immunodeficiency Virus) patients, or with 
cessation of immunosuppressive therapy in other patients [39]. IRIS has been described in context 
of infections with most pathogens seen in AIDS [64]–[66]. 
MRI evidence of enlarging and/or gadolinium enhancement of previous CNS lesions supports the 
diagnosis of IRIS in MS patients; however, since the inflammatory brain response occurs before 
MRI changes MRI activity represents a supportive diagnostic finding, not useful in the attempt to 
prevent IRIS onset [67], [68]. 
The IRIS reaction is often clinically important because the removal of natalizumab results in 
renewed immune surveillance, causing a robust inflammatory syndrome. It is possible that the use 
of PLEX, causing a faster removal of the drug from plasma, could lead to a sudden immune 
reconstitution and consequently to a more severe IRIS. Nevertheless, this data still needs 
confirmation by controlled studies.    
Currently, there are no evidences of specific and effective treatment for PML; the infection outcome 
depends completely on the individual's immune reconstitution ability to respond to JCV [69]. The 
main and mandatory intervention in the suspicion of PML is the immediate withdrawal of 
natalizumab that had enabled the disease development. Once the PML had confirmed by 
radiological and CSF findings, one of the most diffuse approach is the fast removal of the residual 
plasmatic quote of drug by the use of PLEX [70], [71].   
The 5-HT2A serotonin receptor has been identified as a receptor for JCV in glial cells [72] and the 
use of medications selective for these receptors, such as mirtazapine and risperidone, have been 
shown to inhibit viral entry into unaffected glial cells. These drugs have been used in clinical 
practice in PML patients with conflicting results [73]–[78]. Also the anti-malarial drug mefloquine, 
able to pass the BBB, recently proved to have anti-JCV activity in vitro, blocking the virus 
replication within the infected cells [79]. As for mirtazapine and risperidone, experience with 
mefloquine comes from case reports and case series, in absence of outcome improvement from 
large prospective studies [80]. The use of other drug classes, such as inhibitors of DNA replication 
(Brincidofovir, Ganciclovir, Leflunomide), immune-response modulators (IL-2 and IL-7) and 
passive or active immunization has been reported in case reports or small case series [69]. 
Many patients with PML experience rapid worsening of neurologic symptoms after PLEX due to 
the occurrence of IRIS.  PML-IRIS is also observed in the absence of PLEX, even though in these 
cases it tends to occur later, approximately 90 days after last dose [51], [81], [82]. 
Corticosteroids are used in the majority of the PML-IRIS patients to reduce the inflammation and to 
improve the associated clinical symptoms. 
There are 2 different approaches in the use of corticosteroids for the management of the PML-IRIS: 
pulse corticosteroids alone or prolonged corticosteroid course with slowly tapering regimens 
alternating with pulse corticosteroids. Tan and coll. [83] reported data on 42 patients with 
natalizumab related PML-IRIS observing that early corticosteroids had no effect on the subsequent 
development of IRIS while the administration of corticosteroids after the IRIS onset seems to be 
associated with favorable EDSS outcomes. Scarpazza and coll. [84] analyzed data on 40 Italian 
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PML patients observing that PLEX did not improve the clinical outcome and that corticosteroids 
administered out of the IRIS onset are associated to a negative disability progression. Landi and 
coll. [85] also compared the clinical outcome and survival of 227 MS cases on the basis of the use 
of PLEX after PML diagnosis: their results did not show improvement of clinical outcome and 
survival with PLEX (36.5% of good outcome in the PLEX group versus 44% in the non-PLEX 
group; 84% of survival in the PLEX group versus 88% in the non-PLEX group). 
Average survival is estimated 77% in natalizumab-related PML patients [86], with a low mortality 
rate in comparison with HIV-PML cases in HIV treated patients [39], [86].Positive prognostic 
features for survival in MS PML subjects are: younger age, lower pre-PML EDSS, lower JCV load 
in CSF, unifocal MRI lesion and earlier diagnosis [87], [88]. PML and IRIS diagnostic, clinical 
features and therapeutic options are summarized in Table 2. 
 
7) Malignancies 
Clinical trials on natalizumab didn't show significant differences in malignancies incidence between 
natalizumab treated patients and control groups [13-15]. However, there are a few authors reporting 
the onset of lymhpoma in MS natalizumab treated patients during the post-marketing phase. In par-
ticular, there are 6 case reports in literature describing the onset of primary central nervous system 
lymphoma (PCNSL) during natalizumab treatment (5 MS patients and 1 patient affected by Crohn 
disease) [89]. All authors reported an Epstein-Barr virus (EBV)-negative B-cell lymphoma, raising 
doubts on the immunosuppressant effect of natalizumab as a causative agent for the PCNSLs devel-
opment, given the pivotal role of EBV in the PCNSL onset in immunocompromised patients. In ad-
dition, natalizumab pre-clinical toxicology studies didn't found evidence of immunosuppression-
related lymphoproliferative diseases in nonhuman primates, even when using doses 10 times higher 
than dose used in human patients [90].  
Schowinsky and coll. [91] reported one case of peripheral T cell lymphoma occurring in a MS pa-
tient after 17 infusions of natalizumab, without evidence of EBV-driven etiology, while a few cases 
of melanoma occurring during natalizumab therapy have been also observed [92]. A prospective 
study on 775 melanocytic skin lesions in 74 MS patients treated with natalizumab found changes in 
only 1.54% of cases and histologic analysis revealed all the excised lesions to be benign [93]. 
Finally, Rolfes and coll. in 2013 reported 4 cases of cervical dysplasia in patients treated with na-
talizumab [94], questioning whether immune suppression related to natalizumab could be responsi-
ble for the persistence of an HPV infection and subsequently cervical dysplasia. However, to our 
knowledge, no further associations between HPV infection and natalizumab patients have been re-
ported since then.  
 
8) Withdrawal issues 
Several studies show that after natalizumab discontinuation a disease activity worse than pre-
natalizumab status, may occur [95]–[97], indicating a rebound effect, similar to an immune 
reconstitution inflammatory syndrome [98]. A recent study [99] who had reached clinical and 
radiological stability after 24 natalizumab courses demonstrated a 4 fold higher ARR after one year 
of withdrawal in 73 natalizumab quitters compared with 35 continuers; however no rebound activity 
was observed in this cohort [89]. Lo Re et al. [100] observed 132 MS patients treated with 
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natalizumab, whose 37 patients remained therapy-free; a significant higher risk of both clinical and 
radiological relapses were observed in natalizumab quitters when compared with natalizumab 
continuers after a 1 year. On the other hand, a French observational study [101] on a very large 
population of 4055 MS patients reported data on 198 patients who remained therapy free for at least 
1 year after natalizumab withdrawal; their ARR was lower than before natalizumab start. A recent 
study [102] compared two different modalities of natalizumab discontinuation, taper protocol versus 
the standard immediate discontinuation, evaluating the following 1-year disease activity; a 
statistically significant higher relapse rate was observed in the standard protocol group in 
comparison to the tapering protocol group. 
Some studies [85], [87], [88] did not observed a beneficial effect on disease activity by switching 
from natalizumab to a first-line therapy in comparison to the therapeutic holiday; thus, also in 
consideration of the cost/benefit ratio, it could be more appropriate to stop any treatment in case of 
decision not to continue with other second-line treatments. Other studies [103], [104] attempted to 
evaluate the effect of steroids on disease activity during the natalizumab wash-out period; the 
results are contradictory and further studies are needed to expand the sample population and clarify 
the potential utility of steroids in this context. 
Recently, Alping and coll. [105] confirmed the potential utility of rituximab in the treatment of 
patients interrupting Natalizumab for JCV virus positivity; indeed, they observed on a cohort of 256 
patients a higher efficacy and safety of rituximab when compared to the other second-line treatment 
fingolimod. 
9) Conclusion 
Natalizumab therapy for MS patients has been demonstrated to be highly effective in several 
clinical trials. The evidence is very strong both for clinical as well for MRI outcomes. Natalizumab 
was firstly approved by FDA in 2004 and withdrew from the market in 2005 for two cases of PML 
in MS patients. After its reintroduction into the market in 2006 a strict surveillance plan has been 
promoted in order to control and to define natalizumab safety profile. In the post-market 
observation, hepatobiliary disorders of different degrees of liver injury associated with natalizumab 
have been reported; 22 of them were referred to liver failure and 12 to autoimmune hepatitis [27], 
emphasizing the attention that need to be paid to liver function before and during natalizumab 
therapy. At the same time, some reports on the association between the use of natalizumab and the 
onset of malignancies such as lymphoma, melanoma and cervical dysplasia should arise the 
attention of clinicians on the surveillance of natalizumab treated patients, although a clear 
association between natalizumab and malignancies has not been yet demonstrated.  
PML represents a potentially fatal SAE and its prevalence is progressively increased since 
natalizumab returned back to market in 2006. There are very important keys to be considered in 
PML management starting from the PML risk evaluation for each patient, the clinical and 
radiological follow up and their timing in order to identify a possible PML as soon as its first 
manifestation. Furthermore, considering natalizumab PML related as a different disease than those 
related to other immunosuppressed patients, like those with HIV or cancer, it seems to have a 
different outcome. Once an MS natalizumab treated patient develops PML, the first step consists in 
stopping therapy and in observing a "wait and watch" interval of time, until the IRIS has became 
clinically evident that is the right time to treat patients with high dose of corticosteroids. 
Nonetheless, natalizumab related PML represents a potentially fatal disease, with frequent and 
severe neurological sequelae in survivors; given the presence of new highly effective disease-
modifying drugs, PML onset should be avoided by accurately balancing benefits and risks for every 
single patient, and considering the switch to other therapies when patients are at high risk of PML 
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development. 
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10) Expert opinion 
In recent years, the progressively greater efficacy of the approved therapy for MS led physicians to 
shift their therapy outcome toward the “disease activity free” patient [106]. This started to be more 
affordable since the MAb were introduced in MS cohort of available therapies. Natalizumab was 
the first approved MAb [9], [10] and the pivotal trials [17], [18] demonstrated about the 70% of 
reduction in ARR and more then 80% of reduction in MRI activity for natalizumab treated patients 
compared to placebo treated ones. The post-marketing studies confirm these results stating for a 
higher efficacy of natalizumab [107], [108]. 
In the pivotal trials [17], [18] the authors did not show significant SAEs in those patients treated 
with natalizumab compared to those who did not receive natalizumab; in particular, infectious side 
effects or malignancies were registered in a very low percentage of patients (around 3% of 
natalizumab treated patients developed infections, other than PML, and less than 1% of natalizumab 
treated patients developed malignancies). The unique high frequency SAEs, highlighted in the 
pivotal trials, were the allergic ones and the ones related to a higher fatigue condition. Some 
different conditions have been pointed out as critical in the post-marketing cohort of studies, in 
particular those related to hepatobiliary disorders since the FAERS received 628 reports, referring to 
the period 2009-2014, of different degrees of liver injury associated with natalizumab and 22 of 
them referred to liver failure and 12 to autoimmune hepatitis [27]. In addition, different 
lymphoproliferative disorders (mostly PCNSL) have been associated with natalizumab treatment, 
although the paucity of cases and the absence of EBV positivity raised more than one doubt on the 
strength of this association.   
 
The PML is a very serious AE, and it has never been reported in MS before natalizumab 
introduction as one of the possible MS therapies. HIV-1 infection remains the most frequent 
immunodeficiency setting for PML, accounting for 80% of cases [109]. The occurrence of PML in 
the context of new therapeutic MAb, which affect certain aspects of leukocyte function, has 
provided new insights into how JCV reactivates to cause PML and the role of leukocytes. 
 
In MS, after the first two cases of PML, natalizumab was withdrawn from the market and 
reintroduced later after a Global Risk Management Plan was defined. At the time of December 
2016, 698 cases of PML were confirmed on a total of over 150.000 patients who received 
natalizumab [24]. When PML firstly occurred, in the MS natalizumab treated cohort of patients, 
neurologists had no specific experience but the one from PML in immunocompromised patients. 
The PML management strategy is to be considered both preventive and interventional, once PML 
has been diagnosed. In order to prevent PML, neurologists should attain to an accurate follow-up 
plan that EMA has recently redefined [110] on the basis of data on risk stratification groups on 
about 21.000 natalizumab treated patients. The PML risk has been defined on three different factors: 
the positivity for anti-JCV antibodies, the number of natalizumab administrations and the JCV 
index level; after 24 natalizumab administration those patients considered to be at higher risk of 
PML should undergo an MRI scan every three months, those with a low (<0.9) or intermediate 
(>0.9 <1.5) index value should repeat the test every six months. 
Unfortunately, once PML has been diagnosed there is no antiviral agent demonstrated as being 
effective against the JCV [69]. Prosperini et al. [82] defined some epidemiological and predictive 
variable stating that natalizumab related PML evolves in a timeframe from 6 to 12 months, with the 
peak of disability at 6 months and a variable recovery at 12 months from diagnosis; that the 
asymptomatic PML and a lower JCV viral load at PML diagnosis are associated with better 
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outcomes. De Rossi et al. [84], of the same group, defined as a better outcome is affordable 
avoiding PLEX and starting steroid not before the IRIS has been initiated with evidence of MRI 
IRIS characteristics. 
Recently, new highly effective drugs have been commercialized for MS treatment but natalizumab 
remains the most efficacious therapy. However, widening the therapeutic options, MS specialists 
have the opportunity to administer a patient-tailored therapy depending on the disease features, the 
patient's preference, and the best risk/benefit drug profile according to the single patient 
characteristics. Our opinion is that natalizumab should be reserved for patients with a severe form 
of MS, possibly considering other therapies in case of anti-JCV Ab positivity and/or history of liver 
dysfunction. A strict monitoring of clinical, laboratory and neuroimaging data is recommended in 
all patients, in spite of the presence of anti-JCV Ab positivity. 
In conclusion, we can affirm that natalizumab remains one of the most efficacious drugs available 
for the MS treatment; nevertheless, challenging problems of safety have been pointed out during the 
last years that need particular attention: if PML and its consequences are considered the most 
relevant safety issues for natalizumab patients, and proved to be not so rare, a continuous 
surveillance must be maintained in all patients also regarding other possible SAEs like liver 
diseases and malignancies. In this context, pathologists and clinicians need continual vigilance for 
"the expected" (PML) as well as ‘‘the unexpected’’ in natalizumab-treated patients.  
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Drug summary box  
 
 
Drug name natalizumab 
Phase Launched 
Indication Multiple sclerosis 
Pharmacology description  
Alpha4beta1 integrin antagonist 
Integrin antagonist 
Alpha4beta7 integrin antagonist 
Alpha4 integrin antagonist 
Route of administration Injectable 
Chemical structure Immunoglobulin G4, anti-(human integrinalpha4) (human-mouse monoclonal 
AN100226 gamma4-chain), disulfide with human-mouse monoclonal AN100226 light 
chain, dimer [CAS] 
Pivotal trial(s) AFFIRM: the Natalizumab Safety and Efficacy in Relapsing Remitting Multiple Scle-
rosis study.  A two-year phase 3 randomized, double-blind, placebo-controlled study  
to confirm the efficacy of natalizumab in relapsing multiple sclerosis and to evaluate 
the safety of long-term treatment.  Enrolled patients were randomized in a 2:1 ratio 
to receive an intravenous infusion of natalizumab 300 mg or placebo every 4 weeks 
for up to 116 weeks. 
SENTINEL: Safety and Efficacy of Natalizumab in Combination With Interferon Beta-
1a in Patients With Relapsing-Remitting Multiple Sclerosis.  A two-year phase 3 ran-
domized, double-blind, placebo-controlled study.  Enrolled patients were randomized 
to receive an intravenous infusion of natalizumab 300 mg or placebo every 4 weeks 
in addition to an intramuscular injection of interferon β-1a (30 μg) once weekly for up 
to 116 weeks. 
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Table 1: Adverse events other than PML 
 
Adverse	event	 Frequency	 Bibliography	
Serious	infection	 3,2%	
2,7%	
4%	
1,9%	
AFFIRM	Trial	[13]	
SENTINEL	Trial	[14]	
STRATA	Study	[21]	
TOP	Study	[22]	
Malignancies	 <1%	
1%	
2%	
0,5%	
AFFIRM	Trial	[13]	
SENTINEL	Trial	[14]	
STRATA	Study	[21]	
TOP	Study	[22]	
Fatigue	 27%	 AFFIRM	Trial	[13]	
Infusion	reactions	(hypersensivity)	 24%	(4%)	
24%	(1,9%)	
5%	
0,5%	(0,5%)		
AFFIRM	Trial	[13]	
SENTINEL	Trial	[14]	
STRATA	Study	[21]	
TOP	Study	[22]	
Gastrointestinal	disorders	 2%	 STRATA	Study	[21]	
Hepatobiliary	disorders	
	
Significant	liver	injury	
<1%	
<1%	
12	case	reports	
AFFIRM	Trial	[13]	
SENTINEL	Trial	[14]	
Antezana	A.	et	al	[23]	
Persistent	natalizumab	antibodies	 6%	
6%	
3%	
3%	
AFFIRM	Trial	[13]	
SENTINEL	Trial	[14]	
STRATA	Study	[21]	
TOP	Study	[22]	
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Table 2: PML and IRIS 
 
PML 
diagnosis 
 
The gold standard for PML diagnosis is the histopathology examination of 
biopsy material. Clinical diagnosis is currently made by clinical 
presentation, MRI findings, and detection of JC virus DNA in CSF. 
Symptoms Cognitive changes; behavioral, motor and language symptoms; visual 
symptoms (especially visual field deficit); seizures. 
MRI T2/FLAIR: areas of hyperintensitity in the white matter with a peripheral, 
bilateral and asymmetric distribution. Small punctate T2 lesions may be in 
proximity to the lesions. Subcortical rather than periventricular location, 
affecting U-fibers. 
Early asymptomatic stage: focal hyperintense T2 signal in the juxta-
cortical white matter, most commonly unilobar in the frontal lobe, 
involving U-fibers and also frequently the adjacent grey matter. 
Border ill-defined toward the white matter and sharp toward the cortical 
grey matter (GM). 
T1: lesions become increasingly hypointense, as white matter destruction 
occurs. 
T1-contrast-enhancement: 30-40% at the diagnosis; pattern of 
enhancement variable (patchy, linear, nodular, peripheral or perivascular). 
DWI: varies depending on the stage of the disease and can be negative in 
asymptomatic patients. 
IRIS Sub-acute progression and exacerbation of earlier symptoms of PML within 
days to weeks after natalizumab withdrawal and/or plasma exchange 
therapy, due to recovery of the CNS immune system after a period of 
immunosuppression. 
IRIS diagnosis is performed by MRI evidence of enlarging and/or 
gadolinium enhancement of previous CNS lesions (both PML and previous 
MS lesions).  
Therapy PLEX doesn’t improve clinical outcome (36.5% of good outcome versus 
44% without PLEX; 84% of survival versus 88% without PLEX). 
Medications selective for 5-HT2A receptor (mirtazapine, risperidone): 
conflicting results. 
Anti-malarial drug mefloquine: only case reports and case series. 
Inhibitors of DNA replication (Brincidofovir, Ganciclovir, Leflunomide), 
immune-response modulators (IL-2 and IL-7) and passive or active 
immunization: case reports or small case series. 
Corticosteroids: used in PML-IRIS patients to reduce the inflammation; 2 
different approaches (pulse corticosteroids alone or prolonged 
corticosteroid course with slowly tapering regimens alternating with pulse 
corticosteroid). Corticosteroids administered out of the IRIS onset are 
associated to a negative disability progression in PML patients. 
Prognostic 
factors for 
• Younger age;  
• Lower EDSS before PML onset;  
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PML better 
outcome  
• Lower JCV-DNA load in CSF;  
• Unifocal MRI lesion;  
• Early PML diagnosis.	
 
 
 
